Trial · NCT03070184

Race, Natriuretic Peptides and Physiological Perturbations

NCT03070184, Phase 2, Completed, University of Alabama at Birmingham; results first posted 2025-02-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Race, Natriuretic Peptides and Physiological Perturbations. Trials, record NCT03070184. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03070184

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Race, Natriuretic Peptides and Physiological Perturbations
NCT number: NCT03070184
Status: Completed
Phases: Phase 2
Enrollment: 80 participants, actual
Lead sponsor: University of Alabama at Birmingham
Conditions: Healthy, Pre Hypertension
Interventions: Exercise capacity VO2 max determination, Standardized meals, Exercise challenge, Metoprolol Succinate ER
First posted: 2017-03-03
Last updated: 2025-03-12
Results first posted: 2025-02-27

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Plasma BNP After 6-weeks of Beta-Blocker	6 weeks	Mean percentage change in plasma BNP concentrations in response to 6 weeks of Beta-Blocker between Black participants and White participants
Primary	Change in Plasma NT-proBNP After 6-weeks of Beta-Blocker	6 weeks	Mean percentage change in plasma NT-proBNP concentrations in response to 6 weeks of Beta-Blocker between Black participants and White participants
Primary	Change in Plasma MR-proANP After 6-weeks of Beta-Blocker	6 weeks	Mean percentage change in plasma MR-proANP concentrations in response to 6 weeks of Beta-Blocker between Black participants and White participants
Secondary	Change in Plasma BNP After Standardized Exercise Challenge	Mean percentage change in plasma BNP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)	Mean percentage change in plasma BNP concentrations in response to exercise
Secondary	Change in Plasma NT-proBNP After Standardized Exercise Challenge	Mean percentage change in plasma NT-proBNP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)	Mean percentage change in plasma NT-proBNP concentrations in response to exercise
Secondary	Change in Plasma MR-proANP After Standardized Exercise Challenge	Mean percentage change in plasma MR-proANP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)	Mean percentage change in plasma MR-proANP concentrations in response to exercise

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change in Plasma BNP After 6-weeks of Beta-Blocker	6 weeks	Percentage Change in Plasma BNP levels	MEAN
PRIMARY	Change in Plasma NT-proBNP After 6-weeks of Beta-Blocker	6 weeks	Percentage Change in Plasma NT-proBNP	MEAN
PRIMARY	Change in Plasma MR-proANP After 6-weeks of Beta-Blocker	6 weeks	Percentage Change in Plasma MR-proANP	MEAN
SECONDARY	Change in Plasma BNP After Standardized Exercise Challenge	Mean percentage change in plasma BNP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)	Percentage change in Plasma BNP	MEAN
SECONDARY	Change in Plasma NT-proBNP After Standardized Exercise Challenge	Mean percentage change in plasma NT-proBNP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)	Percentage change in Plasma NT-proBNP	MEAN
SECONDARY	Change in Plasma MR-proANP After Standardized Exercise Challenge	Mean percentage change in plasma MR-proANP concentrations from baseline to 20 minutes post-exercise (immediately after exercise)	Percentage change in Plasma MR-proANP	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Plasma BNP After 6-weeks of Beta-Blocker	Black Participants	45	95% Confidence Interval 7 to 95	Percentage Change in Plasma BNP levels
Change in Plasma BNP After 6-weeks of Beta-Blocker	White Participants	74	95% Confidence Interval 30 to 133	Percentage Change in Plasma BNP levels
Change in Plasma NT-proBNP After 6-weeks of Beta-Blocker	Black Participants	95	95% Confidence Interval 31 to 190	Percentage Change in Plasma NT-proBNP
Change in Plasma NT-proBNP After 6-weeks of Beta-Blocker	White Participants	99	95% Confidence Interval 35 to 193	Percentage Change in Plasma NT-proBNP
Change in Plasma MR-proANP After 6-weeks of Beta-Blocker	Black Participants	18	95% Confidence Interval -5 to 47	Percentage Change in Plasma MR-proANP
Change in Plasma MR-proANP After 6-weeks of Beta-Blocker	White Participants	16	95% Confidence Interval -6 to 44	Percentage Change in Plasma MR-proANP
Change in Plasma BNP After Standardized Exercise Challenge	Black Participants	59	95% Confidence Interval 14 to 114	Percentage change in Plasma BNP
Change in Plasma BNP After Standardized Exercise Challenge	White Participants	61	95% Confidence Interval 20 to 116	Percentage change in Plasma BNP
Change in Plasma NT-proBNP After Standardized Exercise Challenge	Black Participants	11	95% Confidence Interval -28 to 69	Percentage change in Plasma NT-proBNP
Change in Plasma NT-proBNP After Standardized Exercise Challenge	White Participants	23	95% Confidence Interval 20 to 87	Percentage change in Plasma NT-proBNP

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Black Participants	40
Overall Study	STARTED	White Participants	40
Overall Study	COMPLETED	Black Participants	40
Overall Study	COMPLETED	White Participants	40
Overall Study	NOT COMPLETED	Black Participants	0
Overall Study	NOT COMPLETED	White Participants	0

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	Black Participants	6	40	6
other	Headache	Nervous system disorders	White Participants	7	40	7
other	Nausea	Gastrointestinal disorders	Black Participants	5	40	5
other	Nausea	Gastrointestinal disorders	White Participants	6	40	6
other	Vasovagal Response	Nervous system disorders	Black Participants	2	40	2
other	Vasovagal Response	Nervous system disorders	White Participants	3	40	3

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Black Participants	0	40
Total, all-cause mortality	White Participants	0	40
Total, other adverse events	Black Participants	6	40
Total, other adverse events	White Participants	7	40
Total, serious adverse events	Black Participants	0	40
Total, serious adverse events	White Participants	0	40

Source ClinicalTrials.gov

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
9134374	RESULT	PubMed
9357812	RESULT	PubMed
11581560	RESULT	PubMed
16476851	RESULT	PubMed
39948072	RESULT	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
K23HL146887	Race, Natriuretic Peptides and Physiological Perturbations	ARORA, PANKAJ	UNIVERSITY OF ALABAMA AT BIRMINGHAM	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2019 to 2023

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Black Participants vs White Participants: deaths from any cause	Trial comparisons
Black Participants vs White Participants: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03070184

GET https://conductscience.org/api/trials/v1/NCT03070184/registered

API reference For AI assistants